Cogent Biosciences rises after Wainwright raises PT

Cogent Biosciences

08/07/2025 17:26

** Shares of drug developer Cogent Biosciences COGT.O up 5.4% at $9.85

** H.C. Wainwright raises COGT's PT to $22 from $12

** COGT said on Monday its drug, bezuclastinib, showed a statistically significant reduction in symptoms in patients with mastocytosis, a type of blood disorder

** Wainwright says raised probability of approval for bezuclastinib in NonAdvSM to 95% from the prior 60%

** Consider 2025 a landmark year for COGN, which could make it an attractive M&A target as well, brokerage says

** Up to last close, stock up 19.8% YTD

 (Reporting by Juby Babu in Mexico City)

 ((Juby.Babu@thomsonreuters.com;))